Using intravenous thrombolysis for patients on new oral anticoagulants after a stroke
Official title: Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on New Oral Anticoagulants
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT06749834 · Data updated 2026-11-12
This study is testing if a common stroke treatment can safely help people who have recently taken new blood thinners after having a stroke.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 280 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Locations | 2 sites (Hangzhou, Zhejiang and 1 other locations) |
| Status | Recruiting |
| Started | January 27, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | February 24, 2025 |
| Trial ID | NCT06749834 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who have experienced acute ischemic stroke within 24 hours and have taken NOACs within the last 48 hours.
✕Probably not a fit
Patients who have contraindications for intravenous thrombolysis, such as a history of intracranial hemorrhage or severe head trauma, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective cohort study aims to evaluate the safety and efficacy of intravenous thrombolysis (IVT) in patients experiencing acute ischemic stroke (AIS) who have taken new oral anticoagulants (NOACs) within the last 48 hours. The study will recruit patients who meet specific inclusion criteria, including those with clinical signs of AIS and recent NOAC usage. The hypothesis is that IVT can improve neurological outcomes in these patients without significantly increasing the risk of severe bleeding complications. The findings could help redefine treatment guidelines for AIS patients on NOACs.
Why it matters
Potential benefit: If successful, this study could enable more patients on NOACs to receive effective treatment for acute ischemic stroke, potentially improving their recovery outcomes.
How similar studies have gone: While there is limited data on this specific approach, previous animal studies suggest that NOACs do not significantly increase the risk of hemorrhagic transformation, indicating potential for success in this area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with clinical signs of acute ischemic stroke within 24 hours of onset or awakening with stroke (if within 24 hours from the midpoint of sleep). Patients with AIS within 4.5-24 hours of onset must meet the IVT inclusion criteria specified in the guideline 2. Patients with new oral anticoagulants usage within 4-48 hours of onset; 3. Patients ≥ 18 years old 4. Informed consent has been obtained depending on local ethics requirements. Exclusion Criteria: 1. Intended to proceed to endovascular treatment 2. With APTT \>40s 3. Pre-stroke mRS score \> 2 4. Contraindications for IVT: 1\) Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hematoma, etc.) 2) Previous history of intracranial hemorrhage 3) Severe head trauma or stroke history within the last 3 months 4) Intracranial tumors, giant intracranial aneurysms 5) Intracranial or spinal surgery within the recent 3 months 6) Major surgical procedures within the last 2 weeks 7) Gastrointestinal or urinary tract bleeding within the last 3 weeks 8) Active visceral bleeding 9) Aortic arch dissection 10) Arterial puncture in a site within the last 1 week that is not easy to compress and stop bleeding 11) Elevated blood pressure: Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg 12) Acute bleeding tendency, including platelet count \< 100 × 10⁹/L or other conditions 13) Received low-molecular-weight heparin treatment within 24 hours 14) Oral anticoagulants (warfarin) with INR \> 1.7 or PT \> 15 s 15) Blood sugar \< 2.8 or \> 22.22 mmol/L 16) Head CT or MRI indicates large-area infarction (infarction area ≥ 1/3 of the middle cerebral artery supply area) (4) The judgment is left to the discretion of the investigator
Where it's running
-
The First People's Hospital of Wenling
Taizhou, Zhejiang, China Recruiting -
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou
Hangzhou, Zhejiang, China Not yet recruiting
Study contacts
- Study coordinator: Min Lou, PhD, MD
- Email: lm99@zju.edu.cn
- Phone: 8613958007213
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Short-Term outside-in nerve stimulation for acute ischemic stroke
This trial tests whether a 5-day external trigeminal nerve stimulation given after stroke can help more patients recover better than a sham treatment.
-
Sevoflurane vs. Propofol for anesthesia in stroke patients undergoing clot-removal
This study tests whether sevoflurane or propofol used for anesthesia during endovascular treatment of an acute ischemic stroke affects the final brain damage and recovery.
-
Safety of adding NRICM301 to standard care for adults with acute ischemic stroke
This study tests whether adding NRICM301, a traditional Chinese medicine formula, to usual care is safe for adults with acute ischemic stroke.
-
Intracranial Recanalization with LT3001 in Acute Ischemic Stroke
This phase II study tests whether LT3001 given to adults with acute ischemic stroke can help reopen blocked brain arteries.
-
Mobilisation After Endovascular Stroke Treatment
This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.
-
Endovascular therapy plus standard care vs standard care alone for distal and medium vessel strokes
In people with acute ischemic stroke due to distal or medium vessel blockages, this study tests whether adding endovascular treatment to the usual medical care helps improve outcomes compared with medical care alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.